These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 36065106)

  • 21. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical use of biologics for asthma treatment by allergy specialists: A questionnaire survey.
    Kuruvilla M; Ariue B; Oppenheimer JJ; Singh U; Bernstein JA
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):433-439. PubMed ID: 32629016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use.
    Kermani N; Versi A; Gay A; Vlasma J; Jayalatha AKS; Koppelman GH; Nawijn M; Faiz A; van den Berge M; Adcock IM; Chung KF
    Expert Rev Respir Med; 2023; 17(11):965-971. PubMed ID: 37997709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
    Mavissakalian M; Brady S
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
    Chan R; RuiWen Kuo C; Lipworth B
    J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe Asthma and Biologics: Managing Complex Patients.
    Matucci A; Micheletto C; Vultaggio A
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):168-178. PubMed ID: 36059229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different endotypes and phenotypes drive the heterogeneity in severe asthma.
    McDowell PJ; Heaney LG
    Allergy; 2020 Feb; 75(2):302-310. PubMed ID: 31267562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controversies and opportunities in severe asthma.
    Humbert M; Busse W; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):83-93. PubMed ID: 29059087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New perspectives of biological therapy for severe asthma in adults and adolescents.
    Chheang C; Guinand S; von Garnier C; Sartori C
    Swiss Med Wkly; 2022 May; 152():w30176. PubMed ID: 35748315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hot Topic: Precision Medicine for Asthma-Has the Time Come?
    Li X
    Curr Allergy Asthma Rep; 2019 Sep; 19(10):45. PubMed ID: 31486903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe acute asthma at the pediatric intensive care unit: can we link the clinical phenotypes to immunological endotypes?
    van den Berg S; Hashimoto S; Golebski K; Vijverberg SJH; Kapitein B
    Expert Rev Respir Med; 2022 Jan; 16(1):25-34. PubMed ID: 34709100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future of biologics in pediatric asthma: Optimizing response, early introduction, and equitable access to treatment.
    Schepel IRM; Banzon TM; Phipatanakul W
    Ann Allergy Asthma Immunol; 2024 Jan; 132(1):13-20. PubMed ID: 37652232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe asthma phenotypes and endotypes.
    Agache I
    Semin Immunol; 2019 Dec; 46():101301. PubMed ID: 31466925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
    Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
    Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
    Bakakos A; Loukides S; Usmani OS; Bakakos P
    Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rational approach to compare and select biologic therapeutics in asthma.
    Wang E; Wechsler ME
    Ann Allergy Asthma Immunol; 2022 Apr; 128(4):379-389. PubMed ID: 35093555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eosinophilic Asthma.
    Nelson RK; Bush A; Stokes J; Nair P; Akuthota P
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):465-473. PubMed ID: 31786254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.